HIGD1B Inhibitors

HIGD1B inhibitors such as Rotenone, Antimycin A, and Sodium azide disrupt different sites of the electron transport chain, thereby reducing the efficiency of oxidative phosphorylation and potentially affecting HIGD1B if its function is linked to electron transport or the mitochondrial membrane potential. Oligomycin directly inhibits ATP synthase, which could impact HIGD1B if it requires ATP for its activity. CCCP disrupts the proton gradient across the mitochondrial membrane, which could impact HIGD1B if its function is influenced by the membrane potential.

On the other hand, compounds like Atractyloside and Bongkrekic acid that target the adenine nucleotide transporter can affect the transport of ADP and ATP across the mitochondrial membrane, which could influence HIGD1B's function if it depends on the cellular ATP/ADP ratio. Methylene blue and 2-Deoxy-D-glucose can alter the redox state and availability of substrates for the TCA cycle, respectively, which can indirectly influence HIGD1B function by altering the metabolic state of the cell. Finally, Nicotinamide, by affecting NAD+ metabolism, can influence sirtuin and PARP activity, which could affect HIGD1B function if it is dependent on NAD+-related signaling. Metformin's impact on complex I can lead to changes in the cellular energy status, which could indirectly influence HIGD1B activity.